Free Trial

Scilex (SCLX) Competitors

Scilex logo
$16.31 +1.72 (+11.79%)
Closing price 04:00 PM Eastern
Extended Trading
$16.51 +0.20 (+1.23%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCLX vs. AURA, REPL, LBRX, LRMR, ANNX, DMAC, EDIT, ALT, CTNM, and DSGN

Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Aura Biosciences (AURA), Replimune Group (REPL), LB Pharmaceuticals (LBRX), Larimar Therapeutics (LRMR), Annexon (ANNX), DiaMedica Therapeutics (DMAC), Editas Medicine (EDIT), Altimmune (ALT), Contineum Therapeutics (CTNM), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical products" industry.

Scilex vs. Its Competitors

Aura Biosciences (NASDAQ:AURA) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Aura Biosciences has a net margin of 0.00% compared to Scilex's net margin of -179.12%. Scilex's return on equity of 0.00% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aura BiosciencesN/A -64.44% -54.24%
Scilex -179.12%N/A -109.95%

Aura Biosciences has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Scilex has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by insiders. Comparatively, 7.9% of Scilex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aura Biosciences had 1 more articles in the media than Scilex. MarketBeat recorded 1 mentions for Aura Biosciences and 0 mentions for Scilex. Aura Biosciences' average media sentiment score of 0.55 beat Scilex's score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Aura Biosciences Positive
Scilex Neutral

Scilex has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aura BiosciencesN/AN/A-$86.92M-$1.96-2.99
Scilex$44.24M2.56-$72.81M-$29.02-0.56

Aura Biosciences presently has a consensus target price of $20.50, suggesting a potential upside of 249.83%. Scilex has a consensus target price of $630.00, suggesting a potential upside of 3,762.66%. Given Scilex's higher possible upside, analysts plainly believe Scilex is more favorable than Aura Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aura Biosciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67
Scilex
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Aura Biosciences beats Scilex on 9 of the 16 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLX vs. The Competition

MetricScilexMED IndustryMedical SectorNASDAQ Exchange
Market Cap$113.45M$3.42B$6.15B$10.77B
Dividend YieldN/A2.26%5.71%4.83%
P/E Ratio-0.5623.3129.7228.55
Price / Sales2.56271.94499.21189.70
Price / CashN/A45.1236.6160.67
Price / Book-0.5910.4012.016.61
Net Income-$72.81M-$52.62M$3.32B$276.82M
7 Day Performance27.62%2.14%1.54%1.96%
1 Month Performance-42.95%10.90%6.10%2.53%
1 Year Performance-47.81%13.64%61.10%32.80%

Scilex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLX
Scilex
1.9049 of 5 stars
$16.31
+11.8%
$630.00
+3,762.7%
-54.4%$113.45M$44.24M-0.5680Gap Up
AURA
Aura Biosciences
1.7017 of 5 stars
$6.06
+6.9%
$20.50
+238.3%
-50.2%$352.22MN/A-3.0950
REPL
Replimune Group
4.449 of 5 stars
$8.94
+98.7%
$11.00
+23.0%
-29.9%$351.25MN/A-2.76210Analyst Revision
High Trading Volume
LBRX
LB Pharmaceuticals
N/A$16.00
+2.6%
$30.50
+90.6%
N/A$350.11MN/A0.0016Quiet Period Expiration
LRMR
Larimar Therapeutics
3.1992 of 5 stars
$4.35
+3.6%
$16.71
+284.2%
-46.3%$347.67MN/A-2.7930Upcoming Earnings
ANNX
Annexon
1.5253 of 5 stars
$3.16
+0.3%
$12.50
+295.6%
-58.4%$346.14MN/A-2.4560Analyst Forecast
DMAC
DiaMedica Therapeutics
1.0606 of 5 stars
$6.77
+2.9%
$12.33
+82.2%
+54.3%$340.11MN/A-9.8120Analyst Forecast
EDIT
Editas Medicine
4.3604 of 5 stars
$4.14
+9.8%
$5.10
+23.2%
+13.7%$339M$32.31M-1.45230Positive News
Analyst Forecast
Gap Up
ALT
Altimmune
2.214 of 5 stars
$4.00
+4.4%
$17.40
+335.0%
-41.1%$338.02M$20K-3.3950Analyst Forecast
CTNM
Contineum Therapeutics
2.4453 of 5 stars
$11.09
-5.2%
$22.20
+100.2%
-31.6%$328.09M$50M-5.0431Analyst Forecast
DSGN
Design Therapeutics
0.3488 of 5 stars
$5.83
+1.6%
N/A+0.7%$326.88MN/A-5.2140Analyst Forecast

Related Companies and Tools


This page (NASDAQ:SCLX) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners